Physician profile
Leif E Olsson
NPI 1265489306
$5,219.79
in general payments reported to CMS, 2019-2025
32 companies · $854 in 2025
The $854 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $788 · 2020: $534 · 2021: $569 · 2022: $723 · 2023: $864 · 2024: $888 · 2025: $854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,499 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,499.00 |
| Education | $107.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $1,188.70 | 2019-2025 | Xtandi, Myrbetriq, Padcev |
| Pfizer INC. | $798.91 | 2019-2025 | |
| Abbvie INC. | $436.12 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $324.93 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $306.03 | 2023-2025 | Gemtesa, Orgovyx |
| Janssen Biotech, INC. | $262.12 | 2019-2025 | Erleada |
| Tolmar, INC. | $219.98 | 2023-2025 | Jatenzo, Eligard |
| Antares Pharma, INC. | $158.54 | 2021-2024 | Xyosted, Nocdurna, Tlando |
| Myriad Genetic Laboratories, INC. | $147.56 | 2021-2025 | Prolaris |
| Endo USA, INC. | $139.77 | 2024-2025 | Xiaflex, Aveed |
| Ferring Pharmaceuticals INC. | $135.93 | 2019-2025 | Adstiladrin |
| Coloplast Corp | $123.17 | 2019-2025 | |
| Boston Scientific Corporation | $117.95 | 2020 | |
| Dendreon Pharmaceuticals LLC | $115.09 | 2019-2025 | Provenge |
| Endo Pharmaceuticals INC. | $109.07 | 2019-2024 | Aveed, Xiaflex |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blue Earth Diagnostics | $71.11 | 2019-2025 | Posluma |
| Progenics Pharmaceuticals, INC. | $68.22 | 2022-2025 | Pylarify |
| Tolmar Pharmaceuticals, INC. | $58.83 | 2020-2022 | |
| Verity Pharmaceuticals INC. | $53.47 | 2024 | Trelstar |
| Telix Pharmaceuticals | $50.33 | 2023-2024 | Illuccix |
| Acerus Pharmaceuticals Corporation | $47.30 | 2020-2022 | |
| 180 Medical, INC. | $46.89 | 2023-2024 | |
| Myovant Sciences INC. | $35.88 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.55 | 2023 | Stiolto Respimat, Combivent Respimat |
| Profound Medical Corp. | $30.00 | 2025 | Tulsa-Pro |
| Olympus America INC. | $27.42 | 2022 | |
| C. R. Bard, INC. & Subsidiaries | $24.63 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $23.76 | 2022 | |
| Halozyme INC | $19.93 | 2023 | |
| Astrazeneca Pharmaceuticals Lp | $17.13 | 2024 | Farxiga |
| Allergan, INC. | $16.64 | 2019 | |
| Becton, Dickinson and Company | $13.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leif Olsson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.